German Health Data Providers Compared: Claims Data Access, GDNG Compliance and RWE Fit for Pharma Research
Germany has one of the most analytically valuable health data environments in Europe — and one of the most structurally
Pan-European Real-World Data for Pharma: How to Navigate Fragmented Claims Data Across Pan-European Markets for Multi-Market Launch
Most RWE teams in pharma are fluent in US claims logic. They know Optum. They know IBM MarketScan. They know
How to Make the Case for RWE Investment Internally: A Guide to Pharma Data Procurement, GDPR Compliance and Stakeholder Buy-In
Here’s a scenario that will feel uncomfortably familiar to anyone who has tried to initiate a real-world data programme inside
RWE Strategy for Small Pharma: A Strategic Plan for Pharmaceutical Companies Without a Dedicated Real World Evidence Team
Here’s the assumption that gets small and mid-size pharma companies into trouble more often than any other: that real-world evidence
Why Pharma Data Scientists Spend 70% of Their Time on Data Engineering — And How Analysis-Ready RWD Changes That
The pharmaceutical industry has reached an inflection point. Real-world evidence isn’t a nice-to-have anymore—it’s the foundation for every major strategic
Real-World Data Vendor Comparison: How to Evaluate Pharma Data Providers Without the Sales Pitch
Here’s a conversation I have more often than you’d think. A VP of Market Access — smart, experienced, absolutely knows
RWE Strategy for Lean Pharma Teams: How Small and Mid-Size Companies Can Leverage Real-World Evidence Without an Internal Function
You’re the Head of Market Access at a 200-person specialty biotech. Your lead asset is 18 months from a potential
HEOR Simulation and Cost Modeling with Aggregated Insurance Data
The Privacy Paradox Facing Pan-European HEOR Teams Here’s what I’ve noticed after working with dozens of pharma market access teams
HEOR Simulation and Cost Modeling with Aggregated Insurance Data Read Post »